TGV-inhalonix, Inc., presented data on the drug candidate, Mul-1867, to treat antibiotic-resistant lung infections that is showing promise with the mixed bacterial and fungal infections found in cystic fibrosis (CF) patients. The presentation, from an animal ... Read more